Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38

Journal of Clinical Pharmacology

Volumn 49, Issue 8, 2009, Pages 984-998

  Wrishko, Rebecca E ^a   Ernest, C Steven ^a   Small, David S ^a   Li, Ying G ^a   Weerakkody, Govinda J ^a   Riesmeyer, Jeffrey R ^a   MacIas, William L ^a   Rohatagi, Shashank ^b   Salazar, Daniel E ^b   Antman, Elliott M ^c   Wiviott, Stephen D ^c   Braunwald, Eugene ^c   Lan Ni, ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Maximal platelet aggregation; Population pharmacokinetics; Prasugrel; TRITON TIMI 38

Indexed keywords

CLOPIDOGREL; PRASUGREL; R 106583; R 119251; UNCLASSIFIED DRUG;

AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; ST SEGMENT ELEVATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 70349266838     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337942     Document Type: Article

References (28)

1. Niitsu Y., Jakubowski JA, Sugidachi A., Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005 ; 31: 184-194.
2. Jakubowski JA, Winters KJ, Naganuma H., Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007 ; 25: 357-374.
3. Wiviott SD, Braunwald E., McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357: 2001-2015. (Pubitemid 350106708)
4. Bertrand ME, Rupprecht HJ, Urban P., Gershlick AH ; Classics Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 ; 102: 624-629.
5. Braunwald E., Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction- summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002 ; 40: 1366-1374.
6. Van de Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2003 ; 24: 28-66.
7. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004 ; 25: 166-181.
8. Smith SC Jr, Allen J., Blair SN, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006 ; 113: e166 - e286.
9. Steinhubl SR, Feldman TE, Hirshfeld JW Jr, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288: 2411-2420.
10. Yusuf S., Zhao F., Mehta SR, Chrolavicius S., Tognoni G., Fox KA Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345: 494-502.
11. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention- summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006 ; 47: 216-235.
12. Savi P., Herbert JM Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 ; 31: 174-183.
13. Geiger J., Brich J., Hnig-Liedl P., et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2007-2011.
14. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006 ; 34: 600-607.
15. Wiviott SD, Antman EM, Winters KJ Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 ; 111: 3366-3373.
16. Jernberg T., Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27: 1166-1173.
17. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007 ; 50: 555-562.
18. Wallentin L., Varenhorst C., James S. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 ; 29: 21-30.
19. Antman EM, Li YG, Small DS, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
20. Farid NA, McIntosh M, Garofolo F. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:169-179.
21. Takahashi M., Pang H., Kikuchi A., et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LCMS/MS [abstract]. J Am Soc Mass Spectrosc. 2006 ; 17 (suppl 1). 27S.
22. Ernest CS, Heathman MA, Wrishko RE Prediction of prasugrel active metabolite concentrations from two downstream inactive metabolite concentrations using multilinear regression analysis. J Clin Pharmacol. Submitted for publication.
23. Farid NA, Payne CD, Ernest CS, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008 ; 48: 53-59.
24. Karlsson MO, Savic RM Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 ; 82: 17-20.
25. Small DS, Wrishko RE, Ernest CS II. The pharmacokinetics and pharmacodynamics of prasugrel metabolites in elderly healthy subjects [abstract]. Am J Geriatr Cardiol. 2008 ; 17: 137-143.
26. Salazar DE, Ernest CS II, Wrishko RE, et al. Relationship between exposure to the prasugrel active metabolite with TIMI major/minor bleeding in TRITON TIMI-38. Circulation. 2008 ; 118 (suppl 2). S815.
27. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 ; 153: 66e9-66e16.
28. Small DS, Payne CD, Ferguson-Sells LR Increasing concentrations of prasugrel's active metabolite produce increased inhibition of platelet aggregation [abstract]. J Am Coll Cardiol. 2006 ; 47 (suppl 1). 379A - 380A.